Virax Biolabs Group (Virax Biolabs Group) EV-to-FCF : 0.50 (As of May. 11, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Virax Biolabs Group's Enterprise Value is $-3.04 Mil. Virax Biolabs Group's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.05 Mil. Therefore, Virax Biolabs Group's EV-to-FCF for today is 0.50.

The historical rank and industry rank for Virax Biolabs Group's EV-to-FCF or its related term are showing as below:

VRAX' s EV-to-FCF Range Over the Past 10 Years
Min: -210.49 Med: 0.21 Max: 1.86
Current: 0.5

During the past 4 years, the highest EV-to-FCF of Virax Biolabs Group was 1.86. The lowest was -210.49. And the median was 0.21.

VRAX's EV-to-FCF is ranked better than
74.87% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs VRAX: 0.50

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Virax Biolabs Group's stock price is $0.80. Virax Biolabs Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-18.982. Therefore, Virax Biolabs Group's PE Ratio for today is At Loss.

Virax Biolabs Group EV-to-FCF Historical Data

The historical data trend for Virax Biolabs Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group EV-to-FCF Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

EV-to-FCF

-0.32

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-FCF	Get a 7-Day Free Trial			-	-	-	-0.32	-

Competitive Comparison of Virax Biolabs Group's EV-to-FCF

For the Biotechnology subindustry, Virax Biolabs Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's EV-to-FCF falls into.

Virax Biolabs Group EV-to-FCF Calculation

Virax Biolabs Group's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	-3.037	/	-6.049
	=	0.50

Virax Biolabs Group's current Enterprise Value is $-3.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.05 Mil.

Virax Biolabs Group (NAS:VRAX) EV-to-FCF Explanation

Virax Biolabs Group's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.80	/	-18.982
	=	At Loss

Virax Biolabs Group's share price for today is $0.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-18.982.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Virax Biolabs Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.